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SIGNATURES OF ANTI-THOMSEN — FRIEDENREICH ANTIGEN 
ANTIBODY DIVERSITY IN COLON CANCER PATIENTS
O. Kurtenkov, M. Bubina, K. Klaamas*
Department of Oncology and Immunology, National Institute for Health Development,  
Hiiu 42, Tallinn 11619, Estonia
Aim: To determine whether the structural and functional diversities of naturally occurring antibodies to the Thomsen — Frie-
denreich (TF) antigen may be of diagnostic and prognostic value in colon cancer. Materials and Methods: Serum samples were 
taken from patients with colon cancer (n = 94) and healthy controls (n = 64). The level of TF-specific antibody isotypes and their 
sialylation were determined using ELISA and lectin-ELISA with synthetic TF-polyacrylamide conjugate as an antigen and a sialic 
acid-specific Sambucus nigra agglutinin (SNA). The avidity was determined using ammonium thiocyanate as a chaotrope. The ac-
curacy of diagnostics was evaluated using the receiver operator characteristic curve analysis and the survival analysis employing the 
Kaplan — Meier method. Results: Compared to healthy controls, patients with colon cancer exhibited a lower level of anti-TF IgG 
antibodies, significantly lower ratios of TF-specific IgG/IgM and IgG/IgA, an increased SNA reactivity of anti-TF antibodies, 
mostly on account of IgG, and a lower avidity of TF-specific antibodies, especially their SNA-reactive subset. An increased SNA 
reactivity of anti-TF IgG was observed already at the early stages of cancer (p = 0.0004). The decrease of the ratio of IgG/IgM 
and IgG/IgA showed a good accuracy of diagnostics with about 60% sensitivity at 90% specificity. A similar potential was found 
for the SNA binding/IgG level index. The high level of TF-specific IgA antibodies was associated with a lower survival rate (hazard 
ratio = 0.34). Conclusion: This is the first report ever on the colon cancer-related signatures of anti-TF antibody diversity which 
show diagnostic potential, including in early cancer, and prognostic value. The hypersialylation of TF-specific antibodies appeared 
to be a common phenomenon in cancer. The signatures may be used as non-invasive antibody-based markers for colon cancer.
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antibody glycosylation.
Alterations in cell surface glycosylation are often 
observed to take place in cancer cells, being in-
volved in cancer cell adhesion, signaling, and inva-
sion [1–3]. The overexpression of normally cryptic 
O-glycans is a permanent feature of cancers [4–6]. 
The Thomsen — Friedenreich antigen (Galβ1-3GalNAc 
α-O-Ser/Thr) (TF, CD176) is an oncofetal mucin-type 
O-linked disaccharide which is overexpressed in tumor 
cells and is associated with tumor progression and 
meta stasis [7–11]. Naturally occurring TF-specific 
antibodies of different isotypes are widely present 
in the circulation in health and disease [12, 13]. Anti-
TF antibody and TF-specific lectins have been shown 
to inhibit cancer cell proliferation and metastasis 
in TF expressing cells [14–16]. Clinically and experi-
mentally observed prognostic improvements in cancer 
patients with a high level of TF-specific IgG antibodies 
indicate that the TF-specific innate and/or adaptive 
immune response is an important part of cancer im-
munosurveillance, and TF antigen is a promising target 
for cancer immunotherapy [17–22]. However, the 
clinical role of the diversity parameters of TF-specific 
antibodies, including glycosylation and functional ac-
tivity, remains yet unclear.
Several recent studies showed that there were sig-
nificant differences in the glycosylation profile of total 
human serum IgG between non-malignant controls 
and cancer patients [23–25]. Changes in the glycosyl-
ation pattern of antibodies to tumor-related antigens 
or other disease-specific glycans have been studied 
much less [26–28]. We recently showed that naturally 
occurring anti-TF antibodies were very heterogeneous 
in terms of sialylation and avidity. Moreover, some 
alterations in this diversity revealed diagnostic and 
prognostic values for gastric cancer [29, 30].
Colorectal cancer is one of the most common ma-
lignancies in both males and females and the second 
leading cause of cancer death in Western countries 
[31]. Unfortunately, the majority of the current sero-
logical markers (including autoantibody-based) show 
a low diagnostic accuracy in the early stages of cancer 
[32–36].
The primary objective of this study was to confirm 
the idea that the signatures of naturally occurring 
TF-specific antibody such as the level and propor-
tions of different antibody isotypes, their sialylation 
pattern and avidity may be of clinical importance for 
colon cancer diagnostics, staging, and prognostics. 
Our previous and present findings show that some 
changes in TF-specific antibody signatures appear 
to be a common feature for at least two types of can-
cer (gastric, colon) and can be promising in cancer 
diagnostics, including the early stages of the disease, 
and prognosis.
MATERIAL AND METHODS
Subjects. Serum samples were taken from healthy 
blood donors and individuals with histologically veri-
fied colon carcinoma (Table 1). The investigation was 
carried out in accordance with the ICH GCP Standards 
and approved by Tallinn Medical Research Ethics Com-
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mittee, Estonia. A written informed consent was ob-
tained from each subject under study. Tumor staging 
and morphology were based on the histopathological 
(pTNM) classification of malignant tumors. The serum 
samples were stored in aliquots at −20 °C until use.
Table 1. The characteristics of groups under investigation
Group n Male Female Median age (range), years
Donors 64 25 39 50 (24–78)
Colon cancer patients 95 43 52 65 (34–85)
Stage I 21 8 13 70 (37–80)
Stage II 25 11 14 71 (57–85)
Stage III 24 12 12 70 (46–84)
Stage IV 25 12 13 64 (34–79)
TF-specific antibody assay .  The levels 
of anti-TF IgG, IgM and IgA were determined by the 
enzyme-linked immunosorbent assay (ELISA). The 
plates (NUNC Maxisorp, Denmark) were coated 
with a synthetic TF-polyacrylamide conjugate (TF-
PAA, Lectinity, Russia; 10 mol% of carbohydrate) 
in the carbonate buffer, pH 9.6. After the overnight 
incubation, triple washing and blocking with a Su-
perblock solution (Pierce, USA) for 30 min at 25 °C, 
the serum samples diluted 1:25 in PBS-0.05% 
Tween (Tw) were applied for 1.5 h at 25 °C. After 
the subsequent washing with PBS-Tw, the level 
of bound anti-TF antibodies was determined using 
the alkaline phosphatase conjugated goat anti-
human IgG, IgM (Sigma, USA) or IgA (Dako, USA) 
and p-nitrophenylphosphate disodium hexahydrate 
(pNPP, Sigma, USA). The absorbance values were 
read at 405 nm (Tecan Reader, Austria). The optical 
density value (O.D.) of control wells (blank: the Su-
perblock solution instead of serum) was subtracted 
from that of antibody-coated wells and each sample 
was analysed in duplicate. To standardize the assay, 
standard serum (A) was included in each plate for 
IgG determination and lectin binding measurement. 
The interassay variations were minimized by using 
the correction factor (CF): 
CF = 1/(standard serum A values — blank) x 100. 
The results were expressed in relative units (RU): 
RU = sample O.D. value x CF.
SNA lectin reactivity of TF-specific antibodies. 
The lectin reactivity of TF glycotope-specific antibod-
ies was measured in a similar way, except that the 
binding of the neuraminic acid (sialic acid) -specific 
Sambucus nigra agglutinin (SNA) to the absorbed anti-
TF antibodies was determined. The biotinylated SNA 
(Vector Laboratories, Inc., USA) in 10 mmol/l Hepes, 
0.15 mol/l NaCl, 0.1 mmol/l CaCl2, pH 7.5 was applied 
at a concentration of 5 µg/ml for 1.5 h at 25 °C. The 
bound lectin was detected with a streptavidin-alkaline 
phosphatase conjugate (Dako, USA) and pNPP 
(Sigma, USA). The O.D. of control wells (no serum 
sample) was subtracted from that of antibody-coated 
wells to determine the lectin binding. Each sample 
was analysed in duplicate. The value of the SNA bind-
ing to all TF-specific antibodies and the ratio of SNA 
binding to TF-specific IgG, IgM and IgA (SNA/Ig index) 
were determined.
Avidity of TF-specific antibodies. The avidity 
of anti-TF IgG, IgM, or a pool of IgG+IgM+IgA antibod-
ies was determined by ELISA. The plates were coated 
with the synthetic TF-polyacrylamide conjugate in the 
carbonate buffer, pH 9.6, 5 µg per well. After the over-
night incubation at +4 °C, washing with PBS — 0.05% 
Tw and blocking with the Superblock solution as above, 
the serum (diluted 1:25 in PBS — 0.05% Tw) was ap-
plied for 1.5 h at 25 °C. After subsequent washing am-
monium thiocyanate (NH4SCN) as a dissociating agent 
was added at a concentration of 1.25 mol/l for 15 min 
at +25 °C. The bound antibodies were detected with 
the alkaline phosphatase conjugated goat anti-human 
IgG, IgM or anti-(IgG+IgM+IgA) Igs, and pNPP. The 
absorbance values were read at 405 nm. The rela-
tive avidity index was calculated for each sample and 
expressed as the percentage of reactivity remaining 
in the thiocyanate-treated wells in relation to that 
of untreated wells (PBS-Tw instead of chaotrope).
Avidity of SNA-reactive anti-TF antibodies. The 
avidity of SNA-reactive anti-TF antibodies (a pool of all 
isotypes) was determined by ELISA in a similar way. The 
plates (NUNC Maxisorp, Denmark) were coated with 
the synthetic TF-polyacrylamide conjugate as above. 
After the overnight incubation at +4 °C, triple washing 
and blocking with the Superblock solution for 30 min 
at 25 °C, the serum samples (diluted 1:25 in PBS-0.05% 
Tw) were applied for 1.5 h at 25 °C. After subse-
quent washing ammonium thiocyanate (NH4SCN) 
as a dissociating agent was added at a concentration 
of 1.25 mol/l for 15 min at +25 °C. To detect the lectin 
reactive antibodies, the biotinylated SNA (Vector Labo-
ratories, Inc., USA) in 10 mmol/l Hepes, 0.15 mol/l NaCl, 
0.1 mmol/l CaCl2, and at pH 7.5 was applied at a con-
centration of 5 µg/ml for 1.5 h at 25 °C. The bound lectin 
was detected with a streptavidin-alkaline phosphatase 
conjugate and pNPP. The proportion of TF-specific 
antibody SNA reactivity remaining after treatment with 
chaotrope was defined as the avidity index of SNA reac-
tive anti-TF antibodies.
Statistical analysis. The results were analysed 
using the nonparametric Mann — Whitney U test 
or Student’s T-test, where appropriate, and the Pear-
son two-tailed correlation. Survival analysis was car-
ried out by the Kaplan — Meier method, employing 
the Estonian Cancer Registry database. The median 
of the parameters was used as cut-off. The receiver 
operator characteristic (ROC) curve analysis was used 
to evaluate the sensitivity and specificity of changes 
found in colon cancer patients, as well as the accuracy 
of diagnostics. The respective difference between the 
groups was considered to be significant when p ≤ 0.05. 
All calculations were performed using the GraphPad 
Prism 5 and SPSS 15.0 software.
RESULTS
Anti-TF IgG, IgM and IgA antibody levels. Among 
the three Ig isotypes tested, the level of TF-specific IgG 
antibodies was found to be significantly lower in cancer 
patients compared with controls (p = 0.013). Notably, 
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this decrease was mostly observed in patients with 
early cancer (p = 0.0005 in stage I patients) (Fig. 1, a). 
Neither significant changes in the level of IgM and IgA 
anti-TF antibodies (Fig. 1, b, c) nor appreciable interin-
dividual variations in the levels of these isotypes were 
observed at any stage of the disease. The level of IgM 
and IgA was about twice higher than that of IgG anti-
TF antibodies in patients with any stage of the disease.
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Fig. 1. The anti-TF antibody level in controls and cancer pa-
tients by disease stage. Anti-TF IgG (a), anti-TF IgM (b) and 
anti-TF IgA (c) antibody level. Each dot represents one single 
individual and horizontal lines denote group median. p-values 
were calculated using the Mann — Whitney U test and are 
shown for comparison
In donors, a positive correlation between the levels 
of anti-TF IgG and IgM (r = 0.27; p = 0.0295) was es-
tablished, while in cancer patients, the trend towards 
a negative correlation (r = −0.177; p = 0.087) was 
observed (Fig. 2).
A more pronounced difference in IgG and IgA level 
interrelations between the patients and controls was 
revealed, i.e. no correlation in donors (r = −0.033; 
p = 0.8) was observed but there was found a signifi-
cant negative correlation in cancer patients (r = −0.34; 
p = 0.0007). In addition, a positive correlation be-
tween the levels of IgA and IgM level was observed 
only in the cancer group (r = 0.31; p = 0.0024). 
Compared with controls, a significantly lower ratio 
of IgG to IgM (p = 0.0037) and IgG to IgA (p = 0.004) 
was observed in cancer patients, especially in those 
with early (stage I) cancer (Fig. 3, a, b). The IgM/IgA 
ratio was similar in patients and controls (p = 0.96) 
(Fig. 3, c). Thus, the decrease of anti-TF IgG level 
as well as changes in the relative proportion of differ-
ent TF-specific antibody isotypes were characteristic 
of patients with colon cancer.
SNA reactivity of TF antibodies. A pool of all anti-
TF antibody isotypes showed a significantly higher SNA 
reactivity in cancer patients compared with controls 
(p = 0.004). This increase in SNA binding was observed 
mostly in patients with the advanced stages of cancer 
unlike donors (p < 0.0001) or patients with the early 
stages of the disease (p = 0.0006) (Fig. 4).
A significantly higher SNA/IgG index was observed 
in cancer patients (p < 0.0001 for the whole cancer 
group) irrespective of cancer stage (Fig. 5), being sig-
nificantly higher already in stage I patients (p = 0.0013). 
The SNA/IgM and SNA/IgA indexes showed a similar 
trend: p = 0.066 and p = 0.077, respectively (see 
Fig. 5). Thus, the increased SNA reactivity of TF-
specific antibodies observed in patients with colon 
cancer was mostly related to the IgG isotype.
Avidity of anti-TF antibodies in colon cancer 
patients and controls. A significantly lower avidity 
of TF-specific antibodies (a pool of all isotypes) was 
found in colon cancer patients compared with controls 
(p = 0.05). This decrease was associated with all three 
Ig isotypes (p = 0.07, 0.06 and 0.11 for IgG, IgM and 
IgA, respectively) (Fig. 6). A significantly lower avidity 
of TF-specific antibodies (a pool of all isotypes) and 
IgA was observed at all stages of cancer. IgG anti-
bodies exhibited the highest avidity followed by IgA 
and IgM isotypes. A positive correlation between the 
avidity of IgM and IgA antibodies was revealed in both 
colon cancer patients and controls (r = 0.49 and 
0.35, respectively; p < 0.005), but not between the 
avidity of IgM or IgA and IgG isotypes (r = 0.09–0.23; 
p = 0.37–0.19).
The SNA-reactive anti-TF antibodies (all isotypes) 
also showed a significantly lower avidity in cancer 
patients (p = 0.015) irrespective of cancer stage 
(Fig. 7), including patients with early (stage I) can-
cer (p = 0.045); for stage I + II p = 0.028 and for 
stage III + IV p = 0.032. The SNA-reactive anti-TF an-
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tibodies demonstrated a much lower avidity than the 
whole population of TF-specific antibodies (see Fig. 7) 
in both cancer patients (p = 0.0001) and controls 
(p < 0.0001). Interestingly, there was observed a posi-
tive correlation between the avidity  of SNA-positive 
antibodies and the SNA binding values only in patients 
with cancer (r = 0.33; p = 0.0012) but not in controls 
(r = 0.11; p = 0.54), whereas the avidity of all anti-TF an-
tibodies pool showed a trend towards a negative cor-
relation in cancer patients (r = −0.18; p = 0.18). Thus, 
in patients with colon cancer the avidity of anti-TF an-
tibodies was lower already in the early stages of the 
disease. These changes were more associated with 
the SNA-reactive population of TF-specific antibodies.
Diagnostic potential. Using the ROC curve sta-
tistics, the more pronounced cancer-related changes 
in IgG/IgM ratio, SNA binding value, SNA/IgG index, 
and avidity of SNA-reactive anti-TF antibodies were 
considered as possible cancer biomarkers (Table 2).
The decrease of the IgG/IgM ratio in cancer showed 
a rather good diagnostic accuracy especially in early 
(stage I) colon cancer patients (Fig. 8, a): area under 
the curve (AUC) = 0.7566; sensitivity 69.84% and 
specificity 76.19%; the sensitivity at 90% specific-
ity was equal to 60.3%. The IgG/IgA ratio showed 
a similar, slightly lower result (Fig. 8, b). In advanced 
cancer the respective difference between patients 
and controls was much less significant (see Table 2).
The SNA binding values showed a rather low 
discrimination ability: AUC = 0.642, the sensitivity 
was only 21% at 90% specificity. The SNA reactivity 
of anti-TF IgG defined as the SNA/IgG index also dis-
played a moderate sensitivity in early (stage I) cancer: 
AUC = 0.74, sensitivity 65.45% and specificity 71.43% 
(Fig. 8, c), while at the advanced stages of cancer the 
respective values were slightly lower (see Table 2). The 
values of the sensitivity of the SNA/IgA index as well 
as the SNA-positive antibody avidity were in the range 
of 47–65% at a specificity of 63–73% (see Table 2).
Thus the relative proportion of anti-TF antibody 
isotypes and their SNA reactivity may be used as se-
rological biomarkers for colon cancer. Notably, for 
the IgG/IgM ratio the highest sensitivity and speci-
ficity values were obtained just in patients with early 
(stage I) cancer.
Relation to survival. The survival rate of patients 
a with high level of anti-TF antibodies (a pool of all 
isotypes) was found to be worse mostly on account 
of stage III patients (Fig. 9, a, b). A better survival 
was observed only in patients with stage I and II hav-
ing a higher level of anti-TF IgG (HR = 1.62, 95% 
CI 0.65–4.03, p = 0.229) (Fig. 9, c). In contrast, the 
a b
c d
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high level of TF-specific IgA antibodies in cancer 
patients was associated with a worse survival rate 
(HR = 0.59; p = 0.068) mostly in stage II cancer patients 
(HR = 0.34, 95% CI 0.11–1.04; p = 0.059) (Fig. 9, d, e). 
The level of anti-TF IgM was not related to the overall 
survival (p = 0.71), with a slight trend towards a bet-
ter survival of stage III cancer patients having a high 
level of TF-specific IgM (HR = 2.42, 95% CI 0.63–9.3; 
p = 0.19).
Early-stage cancer patients (I + II) with a high IgG/
IgM ratio revealed a better survival (HR = 2.27, 95% 
CI 0.91–5.63; p = 0.077) whereas patients with stage III 
cancer showed a lower survival rate (HR = 0.33, 95% 
CI 0.09–1.16; p = 0.085) (Fig. 9, f, g). There was ob-
served a very similar association of survival with IgA/
IgM ratio: stage I cancer patients (HR = 1.88, 95% 
CI 0.37–9.64) displayed a trend towards a better sur-
vival in contrast to those with stage III cancer whose 
survival was worse (HR = 0.25, 95% CI 0.06–0.96; 
p = 0.044) (Fig. 9, g, h).
The level of SNA binding to a pool of all anti-TF an-
tibody isotypes, as well as the SNA/IgA index, showed 
no association with overall survival (p = 0.32). However, 
the higher SNA/IgG index was associated with a trend 
towards a better survival (HR = 1.51, 95% CI 0.87–2.61; 
p = 0.14) whereas patients with a high SNA/IgM 
index demonstrated a low survival rate (Fig. 9, h, i) 
especially in early (stage I) cancer (HR = 0.159, 95% 
CI 0.027–0.94; p = 0.042). No significant association 
of anti-TF antibody avidity with the overall and stage-
dependent survival was revealed for a pool of all 
antibody isotypes (p = 0.20) as well as for the avidity 
of IgG and IgA. Interestingly, stage I–II cancer patients 
with a higher avidity of SNA-reactive anti-TF antibodies 
exhibited a significantly lower survival rate (Fig. 9, j) 
whereas patients with advanced cancer (stage III + IV) 
demonstrated a slightly opposite trend towards a bet-
ter survival, or no association with survival (stage IV).
Based on the above results, the relative propor-
tion of different TF-specific antibody isotypes as well 
as SNA/IgG index showed a better prognostic potential 
than antibody levels per se.
DISCUSSION
In the past decade, an essential role of glycans 
in the tuning of cellular and humoral immunity has been 
established [37–39]. Having altered post-translational 
modifications and/or aberrantly expressed, tumor-
associated glycans can trigger an immune response 
[1, 2, 10, 33]. Naturally occurring antibodies to tumor-
associated glycans, including the TF glycotope, were 
shown to participate in antibodies-mediated tumor 
defence, and their level was associated with tumor 
progression, metastases, and patients survival [7, 
8, 18–20]. A common trend towards the decrease 
of the level of natural anti-TF antibody in serum was 
found in cancer patients [12, 13, 41]. We suggest that 
it is more likely related to the elimination of pre-existent 
natural antibodies after their interaction with circulat-
ing tumor- or host-derived TF-positive ligands or, due 
to the accumulation of natural anti-TF antibodies in the 
tumor microenvironment with subsequent modifica-
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tions, including alteration of their glycosylation profile. 
In any case, this implies that no appreciable adaptive 
immune response to the TF glycotope was observed 
in cancer patients.
Based on our previous studies on patients with 
gastric cancer [27–30], we assumed that the diversity 
parameters of TF-specific antibodies, such as level 
in serum, isotypes profile, glycosylation (sialylation) 
and avidity, might be used as serological biomark-
ers for colon cancer as well. In addition, an attempt 
to find the integral criteria of clinical importance based 
on interrelations between the parameters studied was 
undertaken.
In the present study, we showed that TF-specific 
antibodies were very heterogeneous in terms of iso-
types profile, sialylation, avidity, and relation to sur-
vival. Besides, changes of some parameters, such 
as IgG/IgM and IgA/IgM ratios and SNA/IgG index, re-
vealed a good diagnostic accuracy at the early stages 
of colon cancer and can be used as novel diagnostic 
biomarkers. The anti-TF IgG level was associated with 
a better survival, which was in accordance with previ-
ously reported findings in patients with gastrointestinal 
or breast cancer [18–20, 40–42]. In order to establish 
whether the relative proportions of different anti-TF an-
tibody isotypes have diagnostic and/or prognostic 
value, we attempted to establish the ratio between 
the levels of TF-specific IgG, IgM and IgA antibodies 
at different stages of colon cancer. The ratios of IgG/
IgM and IgG/IgA were found to be lower at all stages 
of the disease, but the association of IgG/IgM with 
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survival was quite opposite in early and advanced 
cancer (Fig. 9, f, g).
We recently showed that the SNA-reactivity of anti-
TF antibodies in patients with gastric cancer, irrespec-
tive of the disease stage, was significantly higher [29]. 
In the present study, a similar increase in antibodies 
sialylation was found only in stage III–IV colon cancer 
patients (see Fig. 5) and these changes were associ-
ated mostly with the level of IgG antibodies. Notably, 
in contrast to SNA binding to a pool of all anti-TF anti-
body isotypes, the significantly higher SNA/IgG index 
was observed independently of cancer stage. Besides, 
a close association of the increased SNA reactivity 
of anti-TF antibodies with their lower avidity was de-
tected (Fig. 7).
An increased level of alpha2,6-sialylation of serum 
glycoproteins, often observed in tumor cells, protects 
them from humoral and cellular immunity, acting 
as an antirecognition agent and contributing to cells 
being “self”, thus increasing the metastatic potential 
of tumor cells [1, 5, 43–45]. It has been shown that the 
SNA lectin binds preferentially glycans terminated with 
alpha-2,6 sialic acid on the Fab fragments of IgG [46] 
and about 1% of IgG Fc binds the lectin only when 
two sialic acids are present [47, 48]. We speculate 
that the increased expression of sialyltransferases 
frequently observed in cancer cells [49] would lead 
to hypersialylation in the Fab region of TF-specific 
antibodies in situ that may interfere with the antigen — 
antibody interplay, thus influencing the antibody 
avidity. In fact, the decreased avidity of TF-specific 
antibodies in cancer was mostly associated with the 
SNA-reactive antibodies and was observed already 
at a very early stage of cancer (see Fig. 7). Our data 
about the increased sialylation of anti-TF antibodies 
in patients with advanced colon cancer, as well as the 
lower avidity of SNA-reactive antibodies and the stage- 
and antibody isotype-dependent association of the 
IgG sialylation index with survival suggest that the TF-
specific antibody sialylation should strongly influence 
the anti-tumor immunity and may be a promising target 
for cancer immunotherapy.
Another significant finding was that the impact 
of antibodies sialylation profile, as evaluated by the 
SNA/Ig index, on survival may be quite different 
at various stages of cancer (Fig. 9, i, j). A similar 
stage-dependency was observed with IgG/IgM 
ratio (Fig. 9, f, g), indicating that survival analysis 
should be performed in a stage-dependent manner, 
otherwise its association with survival or diagnostic 
potential may be hidden by the above stage-related 
discrepancies.
Given the responsibility of sialylated IgG antibodies 
for anti-inflammatory effects of intravenous immuno-
globulins [34, 51, 52], we suggest that the association 
of a higher SNA/IgG index with a benefit in survival 
(Fig. 9, i) should be related to the inhibition of in situ 
inflammatory reactions, which is known to promote tu-
mor growth [50, 53]. Alternatively, it may be speculated 
that higher sialylated TF-specific antibodies would 
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Fig. 8. Diagnostic potential of anti-TF antibody ratios and SNA/
IgG index in patients with early (stage I) colon cancer as evalu-
ated by the receiver operator characteristic curve analysis: 
a — IgG/IgM; b — IgG/IgA; c — SNA/IgG index
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act as blocking or interfering antibodies, as has been 
shown, for instance, for an increased sialylation of IgG 
against embryonic antigens, which protects the fetus 
in pregnancy [54].
The currently dominating approach in anti-glycan 
antibody studies on cancer patients is the antibody 
levels profiling. The analysis employs multi-glycan 
microarray techniques [35, 55, 56] to find cancer-
specific changes based on antibody profiling and/
or multiplex combination of more informative antibod-
ies. However, given the extremely high structural and 
functional polymorphism of anti-glycan antibodies, 
we believe that a more promising approach might 
be a search for disease-specific antibody subsets. 
The latter may represent only a small subpopulation 
of the whole anti-glycan antibodies pool (to a given 
Ag) where such subsets will be masked by dominant 
antibodies which show no cancer-related changes. 
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Fig. 9. The probability of survival of cancer patients in relation to the level of anti-TF antibody isotypes, their relative proportions 
and SNA reactivity: a — anti-TF Ab level (a pool of all isotypes), all patients (n = 95); b — anti-TF Ab level (a pool of all isotypes), 
stage III patients (n = 24); c — anti-TF IgG level, stage I + II (n = 45); d — anti-TF IgA level, all patients (n = 94); e — anti-TF IgA 
level, stage II (n = 24); f — anti-TF IgG/IgM ratio, stage I + II (n = 45); g — anti-TF IgG/IgM ratio, stage III (n = 24); h — anti-TF IgA/
IgM ratio, stage III (n = 24); i — SNA/anti-TF IgG index, all patients (n = 94); j — SNA/IgM index, all stages (n = 94); k — IgM avidity 
index, stage I (n = 22); l — avidity of SNA-reactive anti-TF antibodies, stage I + II (n = 45). Patients having values lower than, equal 
to (a dashed line) or higher than median (a solid line) were subjected to study using the Kaplan — Meier method. The hazard ratio 
(HR) with a 95% confidence interval and p-values are shown
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This diversity may also explain the rather variable and 
often quite opposite effects of glycan-targeted im-
munotherapeutic attempts [10].
In conclusion, patients with colon cancer dis-
played a higher level of anti-TF-IgM antibodies, 
a lower TF-specific IgG/IgM and IgG/IgA ratios, 
and an increased SNA reactivity of anti-TF antibod-
ies at the advanced stages of the disease mostly 
on account of IgG, and a lower avidity of TF-specific 
antibodies, especially their SNA-reactive subset. The 
higher sialylation of TF specific antibodies in colon 
carcinoma found in this study is in agreement with 
our previous data obtained about patients with gastric 
or breast cancer (manuscript in preparation) in which 
these changes were even more pronounced. Thus 
it appears that the hypersialylation of TF-specific 
antibodies is a common phenomenon in cancer. 
To our knowledge, no analyses of the distribution, 
avidity and sialylation pattern of anti-TF antibody 
isotypes have been performed before for anti-tumor-
associated glycans antibodies in colon cancer and 
these signatures seem to be clinically more promising 
diagnostic and prognostic parameters than just the 
level of antibodies per se.
In summary, we report for the first time on the 
diversity of anti-TF humoral immune response in pa-
tients with colon cancer, which shows the diagnostic 
and prognostic potential. It is important to note that 
some of the cancer-related changes occur in colon 
cancer patients already at the early stage of the 
disease, thus making these changes promising 
serological biomarkers for early cancer diagnos-
tics and screening. Given there are still no reliable 
antibody-based biomarkers for early colon cancer 
[35, 36], our data on the structural and functional 
diversity of TF-specific antibodies merit further study 
to validate naturally occurring anti-glycan antibody 
signatures in a large prospective population in sev-
eral independent cohorts to further decipher the role 
of anti-glycan antibodies in cancer.
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